Investor Relations

About Vivani

Vivani Medical is an emerging biopharmaceutical company developing a pipeline of miniature, ultra long-term drug implants with its proprietary NanoPortal™ platform technology for obesity/weight management and other chronic diseases.

Vivani’s lead drug implant candidates are designed to improve medication adherence and deliver smooth consistent therapeutic levels of GLP-1 – the same class of active pharmaceutical ingredients in Ozempic®, Trulicity® and Wegovy® – for 6 months, 12 months, or longer with a single administration. NPM-139 and NPM-133, are miniature, six-month, GLP-1 (semaglutide) implants under development for obesity/chronic weight management and the treatment of type 2 diabetes, respectively.

NanoPortal™ has broad potential application across a range of molecule types including peptide therapeutics.

Latest Presentation

2026 Investor Presentation

Latest Financial Results

Q2 2026

Quarter Ended June 30, 2026

Latest Annual Filing

For Fiscal Year Ending December 31, 2025

Stock Snapshot

IR Contacts

Company

Vivani Medical, Inc.
1350 S. Loop Road
Alameda, CA 94502
United States
T: 415-506-8462

Investor Relations

Jami Taylor
Investor Relations Advisor
T: 415-506-8462
investors@vivani.com

Transfer Agent

Vstock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436